DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages 392-397

  Gangat, Naseema ^a   Caramazza, Domenica ^a   Vaidya, Rakhee ^a   George, Geeta ^a   Begna, Kebede ^a   Schwager, Susan ^a   Van Dyke, Daniel ^a   Hanson, Curtis ^a   Wu, Wenting ^a   Pardanani, Animesh ^a   Cervantes, Francisco ^a   Passamonti, Francesco ^a   Tefferi, Ayalew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DATA BASE; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; OVERALL SURVIVAL; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; DATABASES AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS INDICATORS; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 79952087335     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2446     Document Type: Article

References (26)

1. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
2. Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:1128-1138, 2010
3. Tefferi A: Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23:8520-8530, 2005
4. Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895-2901, 2009
5. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265, 2000
6. Ballen KK, Shrestha S, Sobocinski KA, et al: Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16:358-367, 2010
7. Passamonti F, Cervantes F, Vannucchi AM, et al: A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703-1708, 2010
8. Tefferi A, Siragusa S, Hussein K, et al: Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype.AmJ Hematol 85:14-17, 2009
9. Hussein K, Pardanani AD, Van Dyke DL, et al: International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 115:496-499, 2010
10. Caramazza D, Begna KH, Gangat N, et al: Refined cytogenetic risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia [epub ahead of print on October 14, 2010]
11. Patnaik MM, Caramazza D, Gangat N, et al: Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 84:105-108, 2010
12. Vardiman JW, Brunning RD, Harris NL: WHO histological classification of chronic myeloproliferative diseases, in Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization classification of tumors: Tumours of the haematopoietic and lymphoid tissues. Lyon, France, International Agency for Research on Cancer Press, 2001, pp 17-44
13. Shaffer LG, Slovak ML, Campbell LJ, et al: ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 2009
14. Tam CS, Abruzzo LV, Lin KI, et al: The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 113:4171-4178, 2009
15. Hidaka T, Shide K, Shimoda H, et al: The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: A prospective survey of 202 cases in Japan. Eur J Haematol 83:328-333, 2009
16. Tam CS, Kantarjian H, Cortes J, et al: Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis. J Clin Oncol 27:5587-5593, 2009
17. Huang J, Li CY, Mesa RA, et al: Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112:2726-2732, 2008 (Pubitemid 351969217)
18. Passamonti F, Rumi E, Elena C, et al: Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol 150:719-721, 2010
19. Okamura T, Kinukawa N, Niho Y, et al: Primary chronic myelofibrosis: Clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73:194-198, 2001 (Pubitemid 33758860)
20. Barosi G, Viarengo G, Pecci A, et al: Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98:3249-3255, 2001
21. Arora B, Sirhan S, Hoyer JD, et al: Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: A prospective evaluation of prognostic value in 94 patients. Br J Haematol 128:42-48, 2005
22. Tefferi A, Lasho TL, Patnaik MM, et al: JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 24:105-109, 2010
23. Tefferi A, Lasho TL, Abdel-Wahab O, et al: IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24:1302-1309, 2010
24. Tefferi A, Lasho TL, Huang J, et al: Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22:756-761, 2008 (Pubitemid 351559282)
25. Guglielmelli P, Barosi G, Specchia G, et al: Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114:1477-1483, 2009
26. Tefferi A, Pardanani A, Lim KH, et al: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23:905-911, 2009